ProCE Banner Series

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

Join us for this interactive ASH satellite symposia featuring experts perspectives on the latest data on the diagnosis and management of cold agglutinin disease (CAD) with the latest clinical developments informing precision medicine, including discussion around patient cases, and the opportunity to get your questions answered by the experts.

Sign up now!

To Register:  Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Friday Satellite Symposium on Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease, preceding the 65th ASH Annual Meeting and Exposition.

  AMA
Who Should Attend

This program is intended for hematologists and other healthcare professionals who care for patients with cold agglutinin disease.

All Events

Advances in Autoimmune Hemolytic Anemia: Targeting the Complement Cascade in Cold Agglutinin Disease

Past Events

December

08

2023

3:30 PM - 5:30 PM Pacific Time (PT)

In-personVirtual

Marriott Marquis San Diego Marina, 333 W Harbor Dr., San Diego, California 92101

Faculty

ProCE Banner Faculty
Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

ProCE Banner Faculty
David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

ProCE Banner Faculty
Deva Sharma, MD, MS

Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN

Topics

Registration & Refreshment: 3:00 PM - 3:30 PM PT

Welcome, Introduction, and Baseline Assessment

  • Pathophysiology and Classification of CAD
    • Diagnostic criteria and current challenges
  • Current Data in the Therapeutic Management of CAD
    • CAD mechanism of action
    • Historical management
    • Targeted therapies: complement pathway inhibition
  • Future Directions
    • Novel agents in development
    • Clinical trial spotlight: key abstracts from ASH

Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Target Audience
This program is intended for hematologists and other healthcare professionals who care for patients with cold agglutinin disease.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners at integrating new agents into treatment of patients with cold agglutinin disease.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the role of complement pathways in the pathophysiology of cold agglutinin disease and associated clinical manifestations in patients with hemolytic anemia
  • Apply current diagnostic criteria for cold agglutinin disease in patients displaying signs and symptoms of autoimmune hemolytic anemia to facilitate an accurate and timely diagnosis
  • Assess the clinical rationale for therapies that inhibit complement-mediated hemolysis in cold agglutinin disease
  • Plan targeted treatment strategies for patients with cold agglutinin disease based on expert recommendations on up-to-date safety and efficacy data and currently approved indications
  • Implement an individualized treatment and supportive care plan for patients with cancer who develop cold agglutinin disease based on patient-specific characteristics

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Sanofi.